WILLIAMS AND JENSEN, PLLC for PHRMA
What was lobbied
5 issue areas, each in the filer's own words, with who lobbied on it and where.
Budget/Appropriations BUD
Issues related to pharmaceutical development; Policies impacting Medicare Part D; Part B and 340 B programs.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JEANNE HAGGERTY | Legislative Correspondent Senator Chuck Grassley and Senate Aging Committee (shared staff), Legislative Aide Senate Finance Committee, Health Policy Coordinator Health Subcommittee Energy and Commerce, Professional Staff Member |
| SUSAN HIRSCHMANN | — |
| MATTHEW B HOEKSTRA | — |
Defense DEF
Issues related to pharmaceutical manufacturing and development.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JEANNE HAGGERTY | Legislative Correspondent Senator Chuck Grassley and Senate Aging Committee (shared staff), Legislative Aide Senate Finance Committee, Health Policy Coordinator Health Subcommittee Energy and Commerce, Professional Staff Member |
| SUSAN HIRSCHMANN | — |
| MATTHEW B HOEKSTRA | — |
Trade (domestic/foreign) TRD
IP Protections related to trade agreements; trade policies impacting pharmaceutical development; potential tariff actions under Section 232 of the Trade Act of 1962. Legislative proposals related to WTO TRIPS Waiver.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ROBERT BUTORA New | Health Policy Advisor, Senator Bill Cassidy; Senior Health Policy Advisor, Representative Leonard Lance, Health Legislative Assistant, Representative Michael Burgess |
| JEANNE HAGGERTY | Legislative Correspondent Senator Chuck Grassley and Senate Aging Committee (shared staff), Legislative Aide Senate Finance Committee, Health Policy Coordinator Health Subcommittee Energy and Commerce, Professional Staff Member |
| SUSAN HIRSCHMANN | — |
| MATTHEW B HOEKSTRA | — |
Medicare/Medicaid MMM
General education about policies impacting pharmaceutical development, approval and reimbursement; Non-interference. Rebates for Medicare Part D. Importation. 340B Program. IPI drug pricing proposal, Medicare Rebate Rule. Drug pricing legislation, Medicare rebate reform, and proposals to impose "most favored nation" pricing on Medicare Part B and D. "Inflation Reduction Act of 2022" (PL 117-169). Pharmacy benefit manager reform proposals. H.R. 1492 and S. 832. H.R. 1, "One Big Beautiful Bill Act", issues related to biopharmaceutical issues Prescription drug pricing issues, particularly related to MFN.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ROBERT BUTORA New | Health Policy Advisor, Senator Bill Cassidy; Senior Health Policy Advisor, Representative Leonard Lance, Health Legislative Assistant, Representative Michael Burgess |
| JEANNE HAGGERTY | Legislative Correspondent Senator Chuck Grassley and Senate Aging Committee (shared staff), Legislative Aide Senate Finance Committee, Health Policy Coordinator Health Subcommittee Energy and Commerce, Professional Staff Member |
| SUSAN HIRSCHMANN | — |
| MATTHEW B HOEKSTRA | — |
Health Issues HCR
General education about policies impacting pharmaceutical development, approval and reimbursement; Non-interference. Rebates for Medicare Part D. Importation. 340B Program. Drug pricing legislation, Medicare rebate reform, and proposals to impose "most favored nation" pricing on Medicare Part B and D. "Inflation Reduction Act of 2022" (PL 117-169). Pharmacy benefit manager reform proposals. H.R. 1492 and S. 832.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ROBERT BUTORA New | Health Policy Advisor, Senator Bill Cassidy; Senior Health Policy Advisor, Representative Leonard Lance, Health Legislative Assistant, Representative Michael Burgess |
| JEANNE HAGGERTY | Legislative Correspondent Senator Chuck Grassley and Senate Aging Committee (shared staff), Legislative Aide Senate Finance Committee, Health Policy Coordinator Health Subcommittee Energy and Commerce, Professional Staff Member |
| SUSAN HIRSCHMANN | — |
| MATTHEW B HOEKSTRA | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.